FGF19 and hepatocellular carcinoma: This is an open-label, single-arm Phase II study focusing on evaluating the efficacy and safety of Futibatinib in combination with Pembrolizumab for the treatment of advanced or metastatic HCC that is FGF19-positive and classified as BCLC Stage A, B, or C. The trial takes 6-month PFS as the primary endpoint, and plans to recruit 25 patients.